Monocyte CD169 Expression as a Biomarker in the Early Diagnosis of Coronavirus Disease 2019.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 33206973.
- Also identified by DOI 10.1093/infdis/jiaa724 and PMC identifier 7717347.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We assessed the expression of CD169, a type I interferon-inducible receptor, on monocytes (monocyte CD169 [mCD169]) in 53 adult patients admitted to the hospital during the coronavirus disease 2019 (COVID-19) outbreak for a suspicion of severe acute respiratory syndrome coronavirus 2 infection. Monocyte CD169 was strongly overexpressed in 30 of 32 (93.7%) confirmed COVID-19 cases, compared with 3 of 21 (14.3%) patients in whom the diagnosis of COVID-19 was finally ruled out. Monocyte CD169 was associated with the plasma interferon-alpha level and thrombocytopenia. Monocyte CD169 testing may be helpful for the rapid triage of suspected COVID-19 patients during an outbreak.
Medical subject headings
- COVID-19
- Monocytes
- Sialic Acid Binding Ig-like Lectin 1